Advertisement
| car t therapy for prostate cancer: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t therapy for prostate cancer: Dr. Patrick Walsh's Guide to Surviving Prostate Cancer Patrick C. Walsh, Janet Farrar Worthington, 2018-05-15 This guide covers every aspect of prostate cancer, from potential causes including diet to tests for diagnosis, curative treatment, and innovative means of controlling advanced stages of cancer. |
| car t therapy for prostate cancer: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t therapy for prostate cancer: Salvage Therapy for Prostate Cancer Sanchia S. Goonewardene, Raj Persad, Karen Ventii, David Albala, Declan Cahill, 2020-11-23 This book comprehensively covers application of salvage therapy in reccurrent prostate cancer. Chapters focus on specific issues associated with a range of surgical and oncological management techniques and strategies including hormone therapy, lymphnode dissection, robotic prostatectomy and salvage reirradiation after locoregional failure. Learning objectives, and definitions of keywords are provided to aid the reader develop a thorough understanding of the topic and reinforce the key points covered in each chapter. Salvage Therapy for Prostate Cancer provides a detailed practically applicable guide on how salvage therapy can be utilised in the treatment of prostate cancer. It represents a valuable resource for trainee and practicing urologists, oncologists, and specialist nurses. |
| car t therapy for prostate cancer: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t therapy for prostate cancer: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t therapy for prostate cancer: Protein Engineering Huimin Zhao, 2021-08-23 A one-stop reference that reviews protein design strategies to applications in industrial and medical biotechnology Protein Engineering: Tools and Applications is a comprehensive resource that offers a systematic and comprehensive review of the most recent advances in the field, and contains detailed information on the methodologies and strategies behind these approaches. The authors—noted experts on the topic—explore the distinctive advantages and disadvantages of the presented methodologies and strategies in a targeted and focused manner that allows for the adaptation and implementation of the strategies for new applications. The book contains information on the directed evolution, rational design, and semi-rational design of proteins and offers a review of the most recent applications in industrial and medical biotechnology. This important book: Covers technologies and methodologies used in protein engineering Includes the strategies behind the approaches, designed to help with the adaptation and implementation of these strategies for new applications Offers a comprehensive and thorough treatment of protein engineering from primary strategies to applications in industrial and medical biotechnology Presents cutting edge advances in the continuously evolving field of protein engineering Written for students and professionals of bioengineering, biotechnology, biochemistry, Protein Engineering: Tools and Applications offers an essential resource to the design strategies in protein engineering and reviews recent applications. |
| car t therapy for prostate cancer: You Can Beat Prostate Cancer Robert Marckini, 2020-01-15 Choosing the right prostate cancer treatment can be a daunting task. This book makes it easy. The first edition was a best seller for 10 years. It received more than 400 Amazon reader reviews, mostly 5-star. The second edition, endorsed by highly respected medical professionals from the most prestigious cancer treatment centers in the world, builds on the original. It's about the author's journey from diagnosis through his exhaustive research, treatment and quality of life after treatment. The book explains in layman's terms the pros and cons of every major treatment option and focuses on a highly effective, non-invasive treatment - proton therapy - that cures cancer and leaves the patient with a higher quality of life and fewer, if any, side effects. It also covers the latest developments in prostate imaging and diagnostic technology. Finally, it presents the 10 steps for taking control of the detection and treatment of your prostate cancer. Newly diagnosed men and their loved ones should read this book. |
| car t therapy for prostate cancer: Stereotactic Body Radiation Therapy Simon S. Lo, Bin S. Teh, Jiade J. Lu, Tracey E. Schefter, 2012-08-28 Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists. |
| car t therapy for prostate cancer: Prostate Cancer Scott M. Dehm, Donald J. Tindall, 2020-01-03 The purpose of this book is to provide a contemporary overview of the causes and consequences of prostate cancer from a cellular and genetic perspective. Written by experts in the fields of epidemiology, toxicology, cell biology, genetics, genomics, cell-cell interactions, cell signaling, hormone signaling, and transcriptional regulation, the text covers aspects of prostate cancer from disease initiation to metastasis. Chapters explore in depth the cells of origin for prostate cancer, its genomic subtypes, neural transcription factors in disease progression, epigenetic regulation of chromatin, and many other topics. This book distinguishes itself from other texts on prostate cancer by its focus on cellular and genetic mechanisms, as opposed to clinical diagnosis and management. As a result, this book will be of broad interest to basic and translational scientists with familiarity of these topics, as well as to trainees at earlier stages of their research careers. |
| car t therapy for prostate cancer: Focal Therapy in Prostate Cancer Hashim Uddin Ahmed, Manit Arya, Peter R. Carroll, Mark Emberton, 2011-12-27 This book comprehensively reviews the potential of focal therapy and discusses why the changing face of prostate cancer warrants a change in the way we treat men with the disease. It deals with the mechanisms by which disease can be localized within the gland and then the different technologies used for focal ablation. Bringing together eminent contributors in one accessible reference, this book introduces focal therapy to all urologists, oncologists, and radiologists who are involved in the treatment of men with prostate cancer. |
| car t therapy for prostate cancer: Cancer Vaccines and Immunotherapy Peter L. Stern, Peter C. L. Beverley, Miles Carroll, 2000-08-17 Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments. |
| car t therapy for prostate cancer: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car t therapy for prostate cancer: Androgen Deprivation Therapy Richard J. Wassersug, PhD, Lauren M. Walker, PhD, John W. Robinson, PhD, R Psych, 2021-07-12 Praise for Androgen Deprivation Therapy: To my knowledge [this] is the only book written in plain language (no medical jargon) explaining what’s happening during ADT, and detailing how to limit and often solve most associated side effects. It should be read by every man undergoing ADT, as well as family members and also healthcare providers. They will find all the details they need to get the most from this treatment... Prof. N. Mottet, MD, PhD, Urologist, Medical Oncologist, Head of the Prostate Cancer Guidelines panel of the European Association of Urology Androgen Deprivation Therapy is the only guide written exclusively about the side effects of hormone therapy. The authors have collaborated with the European Association of Urology to produce this specially revised new edition to serve men affected by ADT across the globe. This comprehensive workbook for prostate cancer patients and their loved ones is filled with practical advice from experts in the field. The book covers a wealth of strategies to help men cope with ADT and maintain a good quality of life while on this treatment. It is not only an informational manual, but a guide for both patients and partners about ways to make changes in their lives that can keep them healthy and positive when the patient is on ADT. New to this Edition: Updates on the physical side effects of ADT and management strategies Expanded information on exercise and nutrition for men diagnosed with prostate cancer Updates on the primary drugs used to treat prostate cancer and extensive drug tables with common brand names worldwide Revisions throughout based on critical feedback from international medical experts in the field of prostate cancer and related disciplines Exercises, activities, worksheets, and other tools to promote discussion and inspire behavioural changes that can reduce the burden of ADT Officially endorsed by the European Association of Urology |
| car t therapy for prostate cancer: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. |
| car t therapy for prostate cancer: Prostate Cancer and the Man You Love Anne Katz, 2015 Prostate cancer is the most commonly diagnosed cancer in men after skin cancer. However this cancer is highly curable and most men live for many years after treatment; only eleven percent of cancer deaths are due to prostate cancer. It is well known that the side effects of the treatment cause more suffering than the disease itself. Side effects of surgery include incontinence and erectile difficulties; radiation therapy leads to urinary and bowel problems; and androgen deprivation (hormone) therapy leads to a broad range of long-term side effects affecting physical and emotional functioning. But it is not only the man who suffers through treatment and its side effects. The partners and spouses of prostate cancer survivors are known to experience distress as the man they love moves through the various stages of diagnosis, treatment, and survival. While prostate cancer is a couples' disease, there is much attention paid to the man with cancer and very little to the person and his partner or spouse, who is his prime supporter and who often struggles to make sense of what has happened and why, and how best to support and take care of him. Prostate Cancer and the Man You Love speaks to the loving partners/spouses of men with prostate cancer, whether soon after diagnosis, or later when the man gets on with the rest of his life. Katz includes both the medical information necessary to understanding the disease and firsthand accounts from cancer patients and survivors and their partners. Tips for communication and problem solving, with both partners and health care teams, are offered throughout. Anyone dealing with prostate cancer will find in these pages comfort and insight, as well as specific advice for coping, healing, and moving forward in the spirit of healing and love. |
| car t therapy for prostate cancer: Prostate Cancer Breakthroughs Jay S. Cohen, 2013 Prostate Cancer Breakthroughs 2014 takes you through the entire diagnostic process, answering your questions and suggesting others to ask, then describing 12 different treatment choices for you to consider. Studies have proven that most men diagnosed with prostate cancer do not need surgery or radiation treatment. Find out how to determine whether you do or don't and what your other options are. |
| car t therapy for prostate cancer: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t therapy for prostate cancer: The First Cell Azra Raza, 2019-10-15 With the fascinating scholarship of The Emperor of All Maladies and the deeply personal experience of When Breath Becomes Air, a world-class oncologist examines the current state of cancer and its devastating impact on the individuals it affects -- including herself. In The First Cell, Azra Raza offers a searing account of how both medicine and our society (mis)treats cancer, how we can do better, and why we must. A lyrical journey from hope to despair and back again, The First Cell explores cancer from every angle: medical, scientific, cultural, and personal. Indeed, Raza describes how she bore the terrible burden of being her own husband's oncologist as he succumbed to leukemia. Like When Breath Becomes Air, The First Cell is no ordinary book of medicine, but a book of wisdom and grace by an author who has devoted her life to making the unbearable easier to bear. |
| car t therapy for prostate cancer: Immune Regulation Marc Feldmann, N. A. Mitchison, 2012-12-06 Leukocyte culture conferences have a long pedigree. This volume records some of the scientific highlights of the 16th such annual con ference, and is a witness to the continuing evolution and popularity of leukocyte culture and of immunology. There is strong evidence of the widening horizons of immunology, both technically, with the obviously major impact of molecular biology into our understanding of cellular processes, and also conceptually. Traditionally, the 'proceedings' of these conferences have been published. But have the books produced really recorded the major part of the conference, the informal, friendly, but intense and some times heated exchanges that take place between workers in tackling very similar problems and systems and which are at the heart of every successful conference? Unfortunately this essence cannot be incorpo rated by soliciting manuscripts. For this reason, we have changed the format of publication, retaining published versions of the symposium papers, but requesting the workshop chairmen to produce a summary of the major new observations and areas of controversy highlighted in their sessions, as a vehicle for defining current areas of interest and debate. Not an easy task, as the workshop topics were culled from the abstracts submitted by the participants, rather than being on predefined topics. The unseasonal warmth in Cambridge was reflected in the atmos phere of the conference, the organization of which benefited from the administrative skills of Jean Bacon, Philippa Wells, Mr. Peter Irving, and Mrs. |
| car t therapy for prostate cancer: Conquer Prostate Cancer Rabbi Edgar J. Weinsberg, Ed Weinsberg, 2008 This inspiring physical, emotional, and spiritual guide empowers patients to face diagnosis with dignity, explore their options realistically, and tackle recovery with optimism and determination. The first book to emphasize robotic surgery for prostate cancer from an informed layman's perspective, CONQUER PROSTATE CANCER discusses the latest research and advances in treatment, and profiles twenty patients who chose various treatment options. As the author and his wife share the most intimate details of their prostate cancer journey, readers learn how to: -- Become an active member of their medical team -- Reduce pain and stress and renew vitality -- Overcome impotence and incontinence -- Enhance intimate relationships -- Draw strength from faith, family, and friends Prominent robotic surgeon Dr. Robert Carey discusses medical and patient-care concerns and the author's wife provides a running commentary, sharing her thoughts about how she and her family coped with the disease and its effects. With its low-key humor, hopeful tone, and well-researched facts, this book is a powerful tool for surviving prostate cancer, and a valuable resource for prostate cancer patients, survivors, and their loved ones, The author, Rabbi Ed Weinsberg, is a prostate cancer survivor and rabbi with a doctorate in gerontology from Columbia University. Contributing author Dr. Robert Carey is a prominent urologist and robotic surgeon with a Ph.D. from MIT. Dr. David Kauder, the book's medical advisor, has been a urologist for the past 30 years and is a past president of the Massachusetts Association of Practicing Urologists. Rabbi Weinsberg draws on his own medical ordeal to bring guidance and comfort to others, says Rabbi Harold Kushner, author of When Bad Things Happen to Good People. Dr. Ellen Kreidman, psychologist and relationship expert appearing on Oprah and other national media calls the book brilliant, inspiring, and gutsy, and says that it will enable its readers to experience the joys of sex again. Successfully wrestles with the concerns of those confronted by prostate cancer, declares Dr. Robert Butler, M.D., President and CEO of the International Longevity Center and a Pulitzer Prize-winning author. Jerry Perisho, prostate cancer survivor, former freelance comedy writer for Jay Leno, David Letterman marveled how this book is crammed full of laughter, stories, remarkable frankness, and great advice. Leah Cohen, a prostate cancer survivor's wife and blog editor states, I applaud the author for recognizing that wives, in their own way, get prostate cancer too. |
| car t therapy for prostate cancer: A Primer on Prostate Cancer Stephen Strum, 2005 A cancer patient's guide to prostate cancer including diagnosis, testing, treatment, and resources. |
| car t therapy for prostate cancer: Management of Prostate Cancer Eric A. Klein, 2004-05-07 This thoroughly updated and revised edition of a widely acclaimed book provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. The authors explain the trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting, and hereditary prostate cancer. Additional chapters reflect progress in the management of locally advanced disease, the use of nomograms to predict outcomes, the medical management of erectile dysfunction, brachytherapy, and deciding between surgery and radiation. A compact disk accompanies the book for downloading the book to a PC or PDA. |
| car t therapy for prostate cancer: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car t therapy for prostate cancer: Bioreactor Systems for Tissue Engineering Cornelia Kasper, Martijn van Griensven, Ralf Pörtner, 2009-02-03 The editors of this special volume would first like to thank all authors for their excellent contributions. We would also like to thank Prof. Dr. Thomas Scheper, Dr. Marion Hertel and Ulrike Kreusel for providing the opportunity to compose this volume and Springer for organizational and technical support. Tissue engineering represents one of the major emerging fields in modern b- technology; it combines different subjects ranging from biological and material sciences to engineering and clinical disciplines. The aim of tissue engineering is the development of therapeutic approaches to substitute diseased organs or tissues or improve their function. Therefore, three dimensional biocompatible materials are seeded with cells and cultivated in suitable systems to generate functional tissues. Many different aspects play a role in the formation of 3D tissue structures. In the first place the source of the used cells is of the utmost importance. To prevent tissue rejection or immune response, preferentially autologous cells are now used. In particular, stem cells from different sources are gaining exceptional importance as they can be differentiated into different tissues by using special media and supplements. In the field of biomaterials, numerous scaffold materials already exist but new composites are also being developed based on polymeric, natural or xenogenic sources. Moreover, a very important issue in tissue en- neering is the formation of tissues under well defined, controlled and reprod- ible conditions. Therefore, a substantial number of new bioreactors have been developed. |
| car t therapy for prostate cancer: Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications Susan C. Frost, Robert McKenna, 2013-10-22 The study of carbonic anhydrase has spanned multiple generations of scientists. Carbonic anhydrase was first discovered in 1932 by Meldrum and Roughton. Inhibition by sulfanilamide was shown in 1940 by Mann and Keilin. Even Hans Krebs contributed to early studies with a paper in 1948 showing the relationship of 25 different sulfonamides to CA inhibition. It was he who pointed out the importance of both the charged and uncharged character of these compounds for physiological experiments. The field of study that focuses on carbonic anhydrase (CA) has exploded in recent years with the identification of new families and isoforms. The CAs are metalloenzymes which are comprised of 5 structurally different families: the alpha, beta, gamma, and delta, and epsilon classes. The alpha class is found primarily in animals with several isoforms associated with human disease. The beta CAs are expressed primarily in plants and are the most divergent. The gamma CAs are the most ancient. These are structurally related to the beta CAs, but have a mechanism more similar to the alpha CAs. The delta CAs are found in marine algae and diflagellates. The epsilon class is found in prokaryotes in which it is part of the carboxysome shell perhaps supplying RuBisCO with CO2 for carbon fixation. With the excitement surrounding the discovery of disease-related CAs, scientists have redoubled their efforts to better understand structure-function relationships, to design high affinity, isotype-specific inhibitors, and to delineate signaling systems that play regulatory roles over expression and activity. We have designed the book to cover basic information of mechanism, structure, and function of the CA families. The authors included in this book bring to light the newest data with regard to the role of CA in physiology and pathology, across phylums, and in unique environmental niches. |
| car t therapy for prostate cancer: Cancer Patient Survival National Cancer Institute (U.S.), 1976 |
| car t therapy for prostate cancer: Therapeutic Antibodies Yuti Chernajovsky, Ahuva Nissim, 2007-11-22 This essential work, edited by two researchers at London’s famous Queen Mary’s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes. |
| car t therapy for prostate cancer: The Breakthrough Charles Graeber, 2015-12-01 Follow along as this New York Times bestselling author details the astonishing scientific discovery of the code to unleashing the human immune system to fight in this captivating and heartbreaking book (The Wall Street Journal). For decades, scientists have puzzled over one of medicine's most confounding mysteries: Why doesn't our immune system recognize and fight cancer the way it does other diseases, like the common cold? As it turns out, the answer to that question can be traced to a series of tricks that cancer has developed to turn off normal immune responses -- tricks that scientists have only recently discovered and learned to defeat. The result is what many are calling cancer's penicillin moment, a revolutionary discovery in our understanding of cancer and how to beat it. In The Breakthrough, New York Times bestselling author of The Good Nurse Charles Graeber guides readers through the revolutionary scientific research bringing immunotherapy out of the realm of the miraculous and into the forefront of twenty-first-century medical science. As advances in the fields of cancer research and the human immune system continue to fuel a therapeutic arms race among biotech and pharmaceutical research centers around the world, the next step -- harnessing the wealth of new information to create modern and more effective patient therapies -- is unfolding at an unprecedented pace, rapidly redefining our relationship with this all-too-human disease. Groundbreaking, riveting, and expertly told, The Breakthrough is the story of the game-changing scientific discoveries that unleash our natural ability to recognize and defeat cancer, as told through the experiences of the patients, physicians, and cancer immunotherapy researchers who are on the front lines. This is the incredible true story of the race to find a cure, a dispatch from the life-changing world of modern oncological science, and a brave new chapter in medical history. |
| car t therapy for prostate cancer: Tumor Microenvironment Alexander Birbrair, 2020-06-25 Revealing essential roles of the tumor microenvironment in cancer progression, this book provides a comprehensive overview of the latest research in the field. A variety of topics are covered, including metabolism in the tumor microenvironment, stellate cells and endothelial progenitors in the tumor microenvironment, as well as the effects of HIV, viral hepatitis, and inflammation in the tumor microenvironment, and more. Taken alongside its companion volumes, Tumor Microenvironment: State of the Science updates us on what we know about various aspects of the tumor microenvironment, as well as future directions. This book is essential reading for advanced cell biology and cancer biology students as well as researchers seeking an update on research in the tumor microenvironment. |
| car t therapy for prostate cancer: Prostate Cancer Unmasked Ray M. Schilling, M.d., 2017-04-20 The FDA approved the PSA test in 1986 as a monitor for treatment response and disease recurrence. Later in 1994 the FDA approved the PSA test as a screening tool for prostate cancer. But the question remained: what was the best treatment tool? I am reviewing 9 different treatment approaches in this book. They are all currently in use by different physicians. But they do not necessarily serve the patient best. Brachytherapy does not quite do it. It improves the cancer for a period of time, and after a few years it returns with a vengeance. The radical prostatectomy and the robotic prostatectomy have helped a significant amount of patients. But long-term studies show that there can be a recurrence rate of as much as 25 to 30%. In addition there are significant side effects like a killed sex life and involuntary dribbling of urine, if the bladder outlet was injured during the surgery. Quite often urologists recommend active surveillance. This approach to prostate cancer means that a 71 to 75 year old prostate cancer sufferer is kept in suspense by the urologist. An initial rectal biopsy is done with a histology assessment where a Gleason score is analyzed. If this score is 6 or less, the cancer is presumed to be less aggressive and active surveillance is done. Another biopsy is done 1 year later and this could go on until the patient dies of a heart attack or a stroke. I think that prostate cancer should be treated early before metastases develop and the cancer gets out of control. There are other methods that actually can get rid of the prostate cancer, for instance cryoablation therapy following a mapping biopsy. In this latter method 60 biopsies are placed like a grid through the entire prostate gland to identify the exact location where prostate cancer has developed. This is done through the perineum (between the scrotum and the anal opening). Prostate cancer can often be multifocal: there may be two or three areas where prostate cancer is located. One month after the mapping procedure probes are introduced in the same way, through the perineum and the identified cancer lesions are treated with cryotherapy twice. I am explaining this in chapter 15 in more detail. According to Dr. Onik, an interventional radiologist in Ft. Lauderdale, active surveillance is something that should be abandoned. Instead the following treatment approach should be adopted. 1. A rising PSA or single PSA above 30 should trigger a referral for a mapping biopsy through the perineal approach under a general anesthetic. The treating physician can sterilize the area and perform biopsies in a sterile fashion, which prevents infection. This is a huge advantage above the standard transrectal approach, which can lead to infections like prostatitis and blood poisoning. 2. Based on the result of the mapping biopsy targeted ablation cryotherapy is performed one month later eradicating all the cancer foci determined through the mapping biopsy. 3. Follow-up PSA levels are obtained every three months for 2 years. If the PSA is less than 3.0, the patient is considered cured. If there is a rising PSA level point 1 and 2 above are repeated until a cure is achieved. Dr. Gary Onik published a 10-year follow-up study that had a 100% survival rate and a 94% cure rate in 70 men with prostate cancer. The reason for such good results is that attention is paid to detail, to the exact location of the cancer and that all cancer is completely eradicated. In my opinion this is the new blueprint of a common sense approach to prostate cancer. Read more details about this in chapter 15. Apart from the above mentioned treatment methods I reviewed external beam radiotherapy, laser ablation therapy and high-intensity focused ultrasound treatment. I noticed that the long-term cure rates over 10 years differ considerably from one treatment modality to the next. All of this is reviewed in detail in this book. |
| car t therapy for prostate cancer: The ABCs of Prostate Cancer Joseph E. Oesterling, Mark A. Moyad, 1997 sands of American families. In The ABCs of Prostate Cancer, two experts explain the facts every man needs to know about this disease. In addition, the book contains testimonials of hope and inspiration from more than 50 well-known survivors of prostate cancer, including Bob Dole, Jerry Lewis, and Sidney Poitier. |
| car t therapy for prostate cancer: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| car t therapy for prostate cancer: The Key to Prostate Cancer Mark Scholz, 2018-01-31 A Guide to Personalized Care. With a self-administered quiz, Key directs readers to targeted information that is stage-specific. Written by 30 leading experts and edited by a prostate oncologist, Key is a welcome antidote for an industry dominated by surgeons. |
| car t therapy for prostate cancer: Lymphocyte Activation L.E. Samelson, H. Renz, 1994 |
| car t therapy for prostate cancer: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| car t therapy for prostate cancer: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| car t therapy for prostate cancer: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| car t therapy for prostate cancer: Clinical and Translational Research in Prostate Cancer Ran Xu, Sifeng Qu, Dong Lin, 2024-01-03 |
| car t therapy for prostate cancer: Transforming Prostate Cancer Care Zodwa Dlamini, |
PSCA-CAR T cell therapy in metastatic castration-resistant …
Chimeric antigen receptor (CAR) T cell therapies have demonstrated durable remissions in hematological malignancies. We report results from a phase 1, first-in-human study of prostate …
CAR T Prostate Cancer Trials
Patients may also have had 1) chemotherapy for castration-sensitive prostate cancer, but not for castration-resistant disease, 2) prior radiotherapy, provided it was rendered > 28 days prior to …
Chimeric Antigen Receptor T Cell Therapies Advanced …
Complexity of Immune Oncology Targets in Advanced Cancer Engineered T-Cell Therapy: CARs, BiTEs, TCRs, and more ‣ Immunotherapy aims to induce anti-tumor response by “active” or …
γδ-Enriched CAR-T cell therapy for bone metastatic castrate
May 3, 2023 · In a preclinical murine model of bone mCRPC, γδ CAR-T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of estab-lished tumors, …
Novel PAP-targeted CAR-T therapy enhances antitumor …
May 31, 2025 · To overcome these problems, we identified prostatic acid phosphatase (PAP, also known as ACPP or ACP3) as a feasible CAR- T target for prostate cancer and developed …
PowerPoint Presentation
Here we show the discovery and preclinical characterization of γδ T cells modified from a set of novel scFv-based CARs targeting PSMA for prostate cancer. We also engineered armored …
Current Landscape and Prospects of CAR-T Cell Therapy in …
This paper talks about the relevant targets of CAR-T therapy for prostate cancer such as PSMA, PSCA, reviews the purpose, process and results of currently approved clinical trials.
CAR T cell therapy for advanced prostate cancer demonstrates …
Saul Priceman, Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and team developed CAR T cells that target prostate stem …
PSMA-Directed CAR T Cells Combined with Low-Dose …
To improve the efficacy of CAR T cells tar-geting prostate carcinoma, we designed a novel CAR that rec-ognizes a new epitope in the prostate-speci fic membrane anti-gen (PSMA) and …
B7-H3 specific CAR-T cells exhibit potent activity against …
Here, we examined the expression of B7-H3 in prostate cancer tissues and cells and developed a second-generation CAR that speci cally targets B7-H3 and CD28 as costimulatory receptor to...
A phase 1b study of PSCA CAR T cells plus or minus radiation …
The primary objective will be to assess the feasibility, safety, and activity of PSCA CAR T cell therapy. Primary endpoints will include evaluation of toxicity through DLT’s and activity through …
CAR-T cell therapy: a potential new strategy against prostate …
In this study we review the principles that have guided the engineering of CAR-T cells and the specific prostatic antigens identified as possible targets for immunological and non …
CAR T-cell therapy for solid tumours - The Lancet
Using a new CAR T-cell technology called synthetic Notch (or synNotch), CAR T cells can be made to target specific cancers very precisely. Researchers at the Children’s Hospital Los …
Development of STEAP1 targeting chimeric antigen receptor …
Chimeric antigen receptors (CARs) that retarget T cells against CD19 show clinical efficacy against B cell malignancies. Here, we describe the development of a CAR against the six …
Introduction to CAR-T Therapy - accc-cancer.org
Oct 7, 2024 · Compare and contrast CAR T-cell therapy to conventional chemotherapy and other immunotherapy modalities. Review current CAR T-cell options and emerging CAR T-cell …
Prostate cancer: Developing CAR T cell therapy - Nature
Current treatments for prostate cancer intended to elicit antitumour immune responses have limited efficacy. Now, researchers have created prostate- tumour-specific CAR T cells by...
Final results from phase I study of PSCA-targeted chimeric …
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC). Background: Chimeric …
The potential of CAR T cell therapy for prostate cancer - Nature
Chimeric antigen receptor (CAR) T cells, based on genetic engineering of the patient’s own T cells for targeted tumour cell lysis, have great potential as immunotherapy for prostate cancer.
Intrinsic ADRB2 inhibition improves CAR-T cell therapy
ADRB2 knockdown CAR-T cells exhibited enhanced cytotoxicity against prostate cancer cell lines in vitro, by increasing CD69, CD107a, GzmB, IFN-g, T-bet, and GLUT-1.
Prevalence of adverse events following T-cell engaging …
Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with met-astatic castrate-resistant prostate …
AstraZeneca at #AACR23
T‑cell engagers Looking to the future, we are exploring ways to redirect T-cells that do not recognise cancer, as they are more abundant and more potent than those that do. To this end, …
325 Armored STEAP2 CAR-T (AZD0754) alone and in …
with the enzalutamide, in prostate cancer PDX models. We found no significant effect of enzalutamide on STEAP2 expression, and our results highlighted the combinatorial activ-ity of …
Prospect of Prostate Cancer Treatment: Armed CAR-T or …
This article discusses the current status and future of CAR-T therapy for prostate cancer. We believe that the enhancement and modification of CAR-T or CAR-T combined with other …
308 Harnessing tumor localized IL-12 to enhance STEAP1 CAR T …
308 Harnessing tumor localized IL-12 to enhance STEAP1 CAR T cell ...
CAR-T therapy in solid tumors - Cell Press
only 5.26 months.21 The progression of CAR-T cell therapy in gastric cancer is also noteworthy. Claudin18.2 (CLDN18.2), a stomach-specific isoform, is expressed in 70% of primary ...
Car T Prostate Cancer Clinical Trial Copy - archive.ncarb.org
Car T Prostate Cancer Clinical Trial: ... Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy Journeys in Prostate Cancer Treatment …
CAR T cell therapy: looking back and looking forward - Nature
The field of CAR T cell therapy for cancer is in its infancy. Despite ... reported the outcomes of 13 patients treated with CAR T cells targeted to prostate-specific membrane antigen that were ...
γδ-Enriched CAR-T cell therapy for bone metastatic castrate …
May 3, 2023 · CANCER γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer Jeremy S. Frieling1*†, Leticia Tordesillas2*†, Xiomar E. Bustos2, Maria …
Prospect of Prostate Cancer Treatment: Armed CAR-T or …
This article discusses the current status and future of CAR-T therapy for prostate cancer. We believe that the enhancement and modification of CAR-T or CAR-T combined with other …
Prospect of Prostate Cancer Treatment: Armed CAR-T or …
However, there are still obstacles to CAR-T treatment of solid tumors because the physical barrier and the tumor microenvironment inhibit the function of CAR-T cells. In this article, we review …
Inactivation of TGF-β signaling in CAR-T cells - Nature
chimeric antigen receptor (CAR)-T-cell therapy for solid tumors. In Cellular & Molecular Immunology, Liang et al. (2024) reported that ... induced tumor eradication in aggressive …
Car T Therapy Prostate Cancer (Download Only)
Car T Therapy Prostate Cancer eBook Subscription Services Car T Therapy Prostate Cancer Budget-Friendly Options 6. Navigating Car T Therapy Prostate Cancer eBook Formats ePub, …
CAR T cells in cancer therapy - Nature
CAR target23 First CD3ζ chain fusion proteins18–20 Fusion of scFv to CD3ζ chain (T-body)21 Establishment of cGMP CAR T cell manufacturing24 Second-generation CARs (CD28/CD3ζ …
CAR-T cell therapy: a potential new strategy against prostate …
The recent development of chimeric antigen receptor (CAR)-T cell therapy redirected against cancer- specific antigens would seem to provide the means for bypassing immune tolerance …
A phase 1b study of PSCA CAR T cells plus or minus radiation …
patients with PSCA+ metastatic castration-resistant prostate cancer. Peter D. Zang, Suzette Blanchard, HripsimeMartirosyan,Lauren Adkins,Gaurav Dhapola,Stephanie Shishido, Cari …
Prospect of Prostate Cancer Treatment: Armed CAR-T or …
obstacles are solved, CAR-T cells can become a favorable weapon for the treatment of prostate cancer. Keywords: CAR-T cell therapy; immunotherapy; prostate cancer; anti-PD-L1; …
Bispecific PSMA antibodies and CAR-T in metastatic …
prostate cancer, and reviews much of the exciting data emerging within the field. Keywords: bispecific antibody, BiTE, CAR-T, castrate resistant, prostate cancer, PSMA Received: 1 …
Chimeric Antigen Receptor T Cell Therapies Advanced …
Adoptive Cell Therapy with CAR -Modified T Cells is a transformative treatment for refractory cancers Multiple Tumor and Host factors will influence efficacy for prostate cancer CAR …
Armored Bicistronic CAR T Cells with Dominant-negative TGF …
27 diseases. However, CAR T therapy has demonstrated limited efficacy in solid tumors, including 28 glioblastoma (GBM). One of the most important reasons is the immunosuppressive tumor …
Collagen-binding IL-12 expressing STEAP1 CAR-T cells reduce …
Mar 19, 2025 · 43 treatment. Combination immunotherapy of CBD-IL-12 CAR-T cells and immune 44 checkpoint inhibitors eradicated large tumors in an established prostate cancer model, 45 …
shRNA-mediated gene silencing of HDAC11 empowers CAR …
May 21, 2024 · employed in effector (CAR-T) cells via RNA interference (RNAi) technology. This modification led to improved CAR-T cell therapy efficacy against prostate cancer cells both …
Low-dose carboplatin modifies the tumor microenvironment …
microenvironment to augment CAR T cell efficacy in human prostate cancer models ... vation, which is a major barrier to CAR T cell therapy in solid tumors.
Phase 1 study of P-PSMA-101 CAR-T cells in patients with …
Background: P-PSMA-101 is an autologous CAR-T therapy targeting PSMA, with a high percentage of stem cell memory T cells (T SCM) associated with efficacy, safety, and bone …
Advances in PSMA-targeted therapy for prostate cancer
Prostate cancer (PCa), a solid malignant tumor, is associated with the highest incidence rate in men globally and the second highest mortality rate in western countries [1].
Prospect of Prostate Cancer Treatment: Armed CAR-T or
Simple Summary: There is still no effective treatment for advanced prostate cancer. CAR-T therapy is a promising approach; however, many obstacles remain for the treatment of solid …
T-Cell redirecting bispecific antibodies: a review of a novel …
Prostate cancer (PCa) is the second most common cause of cancer ... antigens on the surface of cancer cells. CAR T-cell therapy has demonstrated tremendous success in the treatment of …
Docetaxel enhances the therapeutic efficacy of PSMA-specific …
Conclusions Cooperation of PSMA-specic CAR-T cells and the chemotherapy drug docetaxel can impressively ameliorate antitumor eectiveness against an installed metastatic human prostate …
Prevalence of adverse events following T-cell engaging …
(bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with met-astatic castrate-resistant prostate cancer (mCRPC): A meta-analysis. ... (CAR) T-cell therapy in patients with …
Car T For Prostate Cancer (Download Only) - ncarb.swapps.dev
Car T For Prostate Cancer: Heat Inducible Chimeric Antigen Receptor (CAR) T Cell for Prostate Cancer Therapy Xin Wang,2019 While chimeric antigen receptor CAR therapy has emerged …
PSMA-Directed CAR T Cells Combined with Low-Dose …
D7-CAR T cells elim-inated the prostate cancer cells at significantly lower E:T ratios than did the J591-CAR T cells (Figure 1C; Figure S1D), independent of the source of donor T cells or the …
CAR T cell therapy in solid tumors: A review of current clinical …
L1, and CTLA-4 are used as treatments in pancreatic cancer, CAR T cell therapy is a particularly appealing and emerging therapy con-sideration for this disease. Pancreatic ductal …
PSCA-CAR T cell therapy in metastatic castration-resistant …
(CAR) T cell therapies have demonstrated durable remissions in hematological malignancies. We report results from a phase 1, rst-in-human study of prostate stem cell antigen (PSCA) …
Prospect of Prostate Cancer Treatment: Armed CAR-T or
Simple Summary: There is still no effective treatment for advanced prostate cancer. CAR-T therapy is a promising approach; however, many obstacles remain for the treatment of solid …
Chimeric antigen receptor-modified T cells therapy in …
Prostate cancer Solid tumor Tumor microenvironment ABSTRACT Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells (CAR- Ts). CAR-T …
PD04-10 PRE-CLINICAL STUDIES TO ADVANCE …
PD04-10 PRE-CLINICAL STUDIES TO ADVANCE ZILOVERTAMAB-BASED ANTI-ROR1 DUAL SPECIFICITY CAR T-CELL THERAPY FOR METASTATIC PROSTATE CANCER. Christina …
Lab on a Chip
affect tumor cell (prostate cancer cell line DU145) growth, ... in suppression of CAR-T cell therapy. Experimental Cell culture The Human prostate cancer cell line DU145 (ATCC HTB-81) was …
Prospect of Prostate Cancer Treatment: Armed CAR-T or …
and survivability of CAR-T cells. In this article, we review studies of CAR-T cells in the treatment of prostate cancer, and discuss the prospects for prostate cancer treatment by armed CAR-T …
Chimeric cytokine receptor enhancing PSMA-CAR-T cell …
T (CAR-T) cells has emerged as a preferred therapeutic mod-ality to treating patients with refractory cancer.The success of CD19 CAR-T cell immunotherapy of B-cell malignancies has …
Trends in OPEN ACCESS Cancer - Cell Press
B7-H3 CAR-T cellsh B7-H3-targeted auto-CAR-T. Cell Infusion in patients with B7-H3-positive advanced solid tumors including PCa Unknown, February 2021 NCT04432649 (Phase 1/2) B7 …
POTENSI CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T CELL) …
MODIFIED BY CRISPR/CAS9 AS PROSTATE CANCER THERAPY ABSTRACT Introduction: ... (CAR-T Cell), CRISPR/Cas9, Prostate Cancer, and Prostate-Specific Membrane Antigen …
against prostate cancer B7-H3 specic CAR-T cells exhibit
chimeric antigen receptor (CAR) T cell therapy has overcome cancer immune tolerance and made signicant breakthroughs in liquid cancer treatment. CAR is an articial T cell receptor consisted …
CAR-T cell therapy: a potential new strategy against prostate …
Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor …
Car T Therapy For Prostate Cancer Copy - archive.ncarb.org
Car T Therapy For Prostate Cancer Delve into the emotional tapestry woven by Emotional Journey with in Experience Car T Therapy For Prostate Cancer . This ebook, available for …
γδ-Enriched CAR-T cell therapy for bone metastatic castrate …
CANCER γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer Jeremy S. Frieling1*†, Leticia Tordesillas2*†, Xiomar E. Bustos2, Maria Cecilia Ramello2, …
Prostate cancer surface targets for CAR T cell therapy or …
Prostate cancer surface targets for CAR T cell therapy or metastatic prostate cancer in the CAR T cell era: My kingdom for the target! Cell Ther Transplant 2019; 8(4): 19-28.
γδ-Enriched CAR-T cell therapy for bone metastatic castrate …
May 3, 2023 · CANCER γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer Jeremy S. Frieling1*†, Leticia Tordesillas2*†, Xiomar E. Bustos2, Maria …
Considering the potential for gene-based therapy in prostate …
Feb 26, 2021 · of prostate cancer gene therapy lags behind that for haematological malignancies2, advances in prostate ... (CAR) T cell therapy are also rapidly expanding. In this …
Dominant-Negative TGF-β Receptor Enhances PSMA …
prostate cancer models. We tested whether the potency of chimeric antigen receptor (CAR) T cells directed to prostate-specific membrane antigen (PSMA) could be enhanced by the co …
Developmental Therapeutics in Metastatic Prostate Cancer: …
Keywords: PSMA; STEAP1; KLK2; PSCA; DLL3; prostate cancer; immunotherapy; bispecific T cell engagers; CAR T; antibody–drug conjugate 1. Introduction An estimated 299,010 new …
